SAB BiotherapeuticsSABS +1.29%26 Return-on-Tangible-Equity is -39.86% as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 1,199 Biotechnology companies, SAB Biotherapeutics ranks better than 76.56% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. SAB Biotherapeutics's annualized net income for the quarter that ended in Mar. 2026 was $-75.48 Mil. SAB Biotherapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $189.37 Mil. Therefore, SAB Biotherapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -39.86%.
The historical rank and industry rank for SAB Biotherapeutics's Return-on-Tangible-Equity or its related term are showing as below:
SABS'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -95.51 Med: -49.03 Max: 109.63
Current: -0.35
During the past 7 years, SAB Biotherapeutics's highest Return-on-Tangible-Equity was 109.63%. The lowest was -95.51%. And the median was -49.03%.
SABS's Return-on-Tangible-Equity is ranked better than 76.56% of 1199
companies
in the Biotechnology industry
Industry Median: -42.4
vs SABS: -0.35
SAB Biotherapeutics (NAS:SABS) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
SAB Biotherapeutics Return-on-Tangible-Equity Related Terms
SAB Biotherapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for SAB Biotherapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SAB Biotherapeutics Return-on-Tangible-Equity Chart
SABS vs SRZN, GLSI, ZNTL: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, SAB Biotherapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SAB Biotherapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SAB Biotherapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where SAB Biotherapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -39.86% mean?
SAB Biotherapeutics (SABS) has a Return-on-Tangible-Equity of -39.86% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SAB Biotherapeutics and its competitors. According to the industry distribution chart, SAB Biotherapeutics ranks #281 out of 1199 companies in the Biotechnology industry, placing it in the top 23.4%.
Is SAB Biotherapeutics' Return-on-Tangible-Equity too high?
SAB Biotherapeutics' current Return-on-Tangible-Equity is -39.86%. Based on the distribution chart, SAB Biotherapeutics ranks #281 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, SAB Biotherapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Return-on-Tangible-Equity compare to SRZN and GLSI?
According to the Biotechnology industry distribution chart, SAB Biotherapeutics ranks #281 out of 1199 companies for Return-on-Tangible-Equity. This places SAB Biotherapeutics in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Return-on-Tangible-Equity is -39.86%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Return-on-Tangible-Equity of -39.86%. The current Return-on-Tangible-Equity is -39.86%. SAB Biotherapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Return-on-Tangible-Equity is -39.86% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
26GF Score
Get the complete analysis for SABS
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SABS has been successfully added to your 
